Get the Stockscreener App
1.98
0.50%
-0.01
After Hours:
1.95
-0.03
-1.52%
Tharimmune Inc stock is traded at $1.98, with a volume of 22,860.
It is down -0.50% in the last 24 hours and down -3.41% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$1.99
Open:
$1.99
24h Volume:
22,860
Relative Volume:
0.02
Market Cap:
$3.83M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.1558
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
-8.33%
1M Performance:
-3.41%
6M Performance:
-43.27%
1Y Performance:
-71.86%
1-Day Range:
$1.95
$2.0448
1-Week Range:
$1.95
$2.1583
52-Week Range:
$1.835
$7.461
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.98 | 3.83M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald
Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan
tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India
tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada
Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN
Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com
Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com
Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune
Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN
Tharimmune announces $2.02M private placement; shares up - MSN
Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World
Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN
Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria
THARTharimmune, Inc. Latest Stock News & Market Updates - StockTitan
Tharimmune secures $2.02 million in private funding - Investing.com
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Eagle-Tribune
Tharimmune Secures $2M Strategic Investment to Advance Chronic Pruritus Treatment Pipeline - StockTitan
Rodman & Renshaw sets price target on Tharimmune shares, rating Buy - Investing.com
Tumor necrosis factor (TNF)-alpha Inhibitor Market Will Witness Growth with Emerging Therapies by 2034 | - EIN News
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 - AccessWire
Tharimmune appoints new board member, cancels Intract merger By Investing.com - Investing.com South Africa
Tharimmune appoints new board member, cancels Intract merger - Investing.com
Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch
Penn State wins trademark case over retailer's use of vintage logos, images - Corsicana Daily Sun
Oil company Phillips 66 faces federal charges related to alleged Clean Water Act violations - Corsicana Daily Sun
Valsoft Corporation Enters the Book Industry Software Space with the Acquisition of Edelweiss - Corsicana Daily Sun
Travelers Capital and TCC Financial Bolster Investor Relations Service, Compliance, and Growth with the Appointment of Mark Breakspear - Corsicana Daily Sun
Oleria Named a Winner in Fast Company's 2024 Next Big Things in Tech Awards - Corsicana Daily Sun
Congratulations to Tenorshare for Winning French Design Award - Corsicana Daily Sun
LQR House Inc. Board of Directors Approves Purchase of Up to $1M Bitcoin as Treasury Reserve Asset and Retention of Up to $10M Crypto Payments on CWSpirits.com - Corsicana Daily Sun
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - Corsicana Daily Sun
Sterling Metals Completes 3D IP Survey at Copper Road, Discovers New Outcrop Areas and Extends Mineralized Footprint - Corsicana Daily Sun
BofA Strengthens Support for Arizona Entrepreneurs through State’s Largest Supplier Diversity Program Impact AZ - Corsicana Daily Sun
Diversified Announces Upcoming Investor Engagement - Corsicana Daily Sun
What's Going On With Tharimmune Shares Monday? - Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts
MSP Recovery announces 1-for-25 reverse stock split to regain Nasdaq compliance - MSN
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada
Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com Canada
What's Going On With Tharimmune Shares Wednesday? - MSN
Tharimmune set to receive European patent for cancer therapy tech - Investing.com
Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan
GC Football: Player of the Week - Corsicana Daily Sun
Hoverfly Technologies Promotes Steve Topping to Chief Operating Officer - Corsicana Daily Sun
Tharimmune Announces Upcoming Conference Presentations - StockTitan
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):